

Date: 09.02.2026

To,  
**BSE Limited**  
The Compliance Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001.

**Scrip Code: 531592**

**Subject: Outcome of the Meeting of Board of Directors held on Monday, February 09, 2026.**

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Monday, February 09, 2026, inter alia, has approved the following items:

1. Considered and approved the Unaudited Standalone & Consolidated Financial Results of the Company along with Limited Review Report of the Auditor for the quarter ended December 31, 2025.

We further inform you that the Board Meeting commenced at 04:00 p.m. today and concluded at 04:40 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

**For Genpharmasec Limited**

SOHAN  
CHATURVEDI

Digitally signed by  
SOHAN CHATURVEDI  
Date: 2026.02.09  
16:42:35 +05'30'



**Mr. Sohan Chaturvedi**  
**Whole time director & CFO**  
**DIN- 09629728**

**Encl:**

1. Un-Audited Standalone & Consolidated Financial Results for the quarter ended December 31, 2025.
2. Limited Review Report of the Auditor.

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
**The Board of Directors of Genpharmasec Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Genpharmasec Limited ('the Company') for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**BILIMORIA MEHTA & CO.**  
CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The review of standalone unaudited financial results for the period ended December 31, 2024, included in the Statement was carried out and reported by Abhishek S Tiwari & Associates who have expressed unmodified conclusion vide their review report dated November 12, 2024 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**

Chartered Accountants

FRN: 101490W

*Akash Mehta*



**Aakash Mehta**

Partner

Membership no. 165824

UDIN: 26165824QNRNBX3158

Place of Signature: Mumbai

Date: February 09, 2026

**GENPHARMASEC LIMITED**  
**CIN: L24231MH1992PLC323914**  
**Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31st December 2025	30th September 2025	31st December 2024	31st December 2025	31st December 2024	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	3,600.83	3,156.37	833.56	7,968.51	1,940.80	3,296.36
II. Other Income	- 142.89	100.02	93.14	325.15	236.75	342.80
<b>III. Total Income (I + II)</b>	<b>3,743.72</b>	<b>3,256.39</b>	<b>926.70</b>	<b>8,293.66</b>	<b>2,177.55</b>	<b>3,639.16</b>
<b>IV. Expenses:</b>						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchase of Stock-in-Trade	3,384.96	3,977.54	822.19	8,485.06	1,972.27	3,000.72
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	213.11	(925.84)	(148.15)	(782.58)	(326.58)	33.76
(d) Employee benefit expense	22.46	29.00	17.83	72.65	49.14	66.81
(e) Finance costs	19.09	7.86	10.60	34.62	21.77	27.75
(f) Depreciation and amortization expense	7.38	4.49	4.58	16.18	9.33	13.31
(g) Other expenses	47.97	25.28	48.19	110.32	105.67	119.00
<b>V. Total Expenses</b>	<b>3,694.95</b>	<b>3,118.32</b>	<b>755.26</b>	<b>7,936.25</b>	<b>1,831.62</b>	<b>3,261.35</b>
<b>VI. Profit before tax (III - V)</b>	<b>48.77</b>	<b>138.06</b>	<b>171.44</b>	<b>357.42</b>	<b>345.93</b>	<b>377.81</b>
<b>Tax expense:</b>						
(1) Current tax	11.77	60.94	43.21	89.52	43.21	68.74
(2) Deferred Tax	(2.77)	(4.47)	17.73	(9.39)	35.42	29.03
(3) Prior Period Tax	(35.86)	-	-	(35.86)	-	-
<b>VII. Total Tax Expense</b>	<b>(26.87)</b>	<b>56.47</b>	<b>60.94</b>	<b>44.27</b>	<b>78.63</b>	<b>97.77</b>
<b>VIII. Profit for the period (VI-VII)</b>	<b>75.64</b>	<b>81.59</b>	<b>110.50</b>	<b>313.15</b>	<b>267.30</b>	<b>280.04</b>
<b>Other Comprehensive Income/(Loss)</b>						
(i) Items that will not be reclassified to Profit and Loss	-	-	-	-	-	-
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	(6.22)	(18.07)	(6.93)	(10.03)	0.31	(81.81)
(d) Income tax effect on above	-	-	-	-	-	-
<b>IX. Total Other Comprehensive Income / (Loss)</b>	<b>(6.22)</b>	<b>(18.07)</b>	<b>(6.93)</b>	<b>(10.03)</b>	<b>0.31</b>	<b>(81.81)</b>
<b>X. Total Comprehensive Income/(Loss) for the year (VIII + IX)</b> (Comprising profit and other comprehensive income for the year)	<b>69.41</b>	<b>63.52</b>	<b>103.57</b>	<b>303.12</b>	<b>267.61</b>	<b>198.22</b>
<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
<b>XI. Earning per equity share</b>						
(a) Basic	0.01	0.01	0.02	0.06	0.05	0.04
(b) Diluted	0.01	0.01	0.02	0.06	0.05	0.04



For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728

Place : Mumbai  
Date : February 09, 2026

**Notes to standalone unaudited financial results for the quarter and nine months period ended December 31, 2025**

1. The unaudited standalone financial results of the Company for the quarter ended December 31, 2025, and nine months period ended December 31, 2025, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended.
2. The Company is primarily engaged in a single business segment in accordance with the requirements of Indian Accounting Standard (Ind AS) 108: *Operating Segments*. Accordingly, no separate segment information has been presented.
3. The unaudited standalone financial results of the Company for the quarter and nine months period ended December 31, 2025, have been reviewed by the Audit Committee on February 09, 2026, and subsequently approved by the Board of Directors at their meeting held on February 09, 2026.
4. During the financial year, the Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business. Accordingly, during the current year, the Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 – Inventories. The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended December 31, 2025, is as follows:  
Decrease in Inventories: Rs. 89.32 Lakhs  
Net Impact on Profit Before Tax: Nil  
Net impact on total comprehensive income: Rs. (19.67) Lakhs
5. During the year ended March 31, 2024, the Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.
6. The results for the quarter ended December 31, 2025, are the balancing figures between in respect of the nine-month period ended results as on December 31, 2025, and the figures in respect of the six-month period ended results as on September 30, 2025. Similarly, the results for the quarter ended December 31, 2024, are the balancing figures in respect of the nine-month period ended results as on December 31, 2024, and the figures for the six-month period ended results as on September 30, 2024.

*Soham*



7. The Government of India has consolidated 29 existing labour legislations into four Labour Codes, namely the Code on Wages, 2019; the Code on Social Security, 2020; the Industrial Relations Code, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively, the "New Labour Codes"), which have been made effective from November 21, 2025.

Based on management's assessment, including an actuarial valuation, the implementation of the New Labour Codes has not resulted in any material incremental impact on the Company's gratuity obligations. Accordingly, no adjustment has been made in the financial results for the quarter. The Company is evaluating the impact of the New Labour Codes on other areas, including the contract workforce. Management does not expect any material impact. The Company continues to monitor the issuance of relevant Central and State Rules and clarifications and will recognise the impact, if any, in the financial statements.

8. Previous period figures have been regrouped/reclassified, as considered necessary, to confirm with current period presentation, wherever applicable.



**Independent Auditor's Review Report on the Quarterly and Year to Date Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
**The Board of Directors of Genpharmasec Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results ('the Statement') of Genpharmasec Limited ('the Holding Company') and its Subsidiaries (the Holding Company and its Subsidiaries together referred to as the "the Group") for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 attached herewith being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities mentioned in Annexure I.



5. Based on our review conducted and procedures performed above as stated in paragraph 3 and based on the consideration of the review reports of the other auditors and unaudited financial results referred to in paragraph 6 & 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of one subsidiary, whose unaudited interim financial results include total revenue of Rs. 278.79 lakhs and Rs. 429.75 lakhs, total net loss after tax of Rs. 133.35 lakhs and Rs. 304.41 lakhs, total comprehensive loss of Rs. 133.35 lakhs and Rs. 304.41 lakhs for the quarter ended December 31, 2025 and period ended on that respectively, as considered in the Statement, which has been reviewed by their independent auditor.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of one of the subsidiaries which is located outside India have been prepared in accordance with accounting principles generally accepted in their respective countries. The Holding Company's management has converted the financial results of such subsidiary located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. The financial results and other financial information reflect total revenue of Rs. Nil and Nil, total Net loss after tax of Rs. 0.01 lakhs and 0.09 lakhs, total comprehensive loss of Rs. 0.01 lakhs and 0.09 lakhs for the quarter ended December 31, 2025 and the period ended on that date respectively. We have reviewed these conversion adjustments made by the Holding Company's management.

The unaudited interim financial results and other unaudited financial information of the subsidiary have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.



**BILIMORIA MEHTA & CO.**  
CHARTERED ACCOUNTANTS

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

8. The review of consolidated unaudited financial results for the period ended December 31, 2024, included in the Statement was carried out and reported by Abhishek S Tiwari & Associates who have expressed unmodified conclusion vide their review report dated November 12, 2024 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**

Chartered Accountants

FRN: 101490W



**Aakash Mehta**

Partner

Membership no. 165824

UDIN: 26165824OEFVCY7495

Place of Signature: Mumbai

Date: February 09, 2026

**Annexure -1**

<b>Sr. No</b>	<b>Particulars</b>	<b>Status</b>
1	Clinigenome India Private Limited	Subsidiary
2	Genpharmasec Middle East DMCC	Subsidiary
3	Derren Healthcare Private Limited	Subsidiary

Note: Derren Healthcare Private Limited has become a subsidiary company with effect from July 25, 2025.



**GENPHARMASEC LIMITED**  
**CIN: L24231MH1992PLC323914**  
**Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31st December 2025	30th September 2025	31st December 2024	31st December 2025	31st December 2024	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	3,982.81	3,263.71	848.41	8,450.85	1,971.21	3,372.18
II. Other Income	98.18	46.48	81.20	214.13	212.54	306.22
<b>III. Total Income (I + II)</b>	<b>4,080.99</b>	<b>3,310.19</b>	<b>929.61</b>	<b>8,664.98</b>	<b>2,183.75</b>	<b>3,678.40</b>
<b>IV. Expenses:</b>						
(a) Cost of materials consumed	170.07	88.77	2.25	271.70	49.26	87.21
(b) Purchase of Stock-in-Trade	3,384.96	3,977.54	788.11	8,485.06	1,957.82	2,960.22
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	220.30	(1,028.69)	(144.72)	(912.98)	(345.70)	27.74
(d) Employee benefit expense	125.45	119.72	30.92	280.13	67.83	99.91
(e) Financial costs	41.14	22.52	15.70	75.92	32.85	43.48
(f) Depreciation and amortization expense	66.50	56.21	9.87	149.31	55.50	81.15
(g) Other expenses	205.80	153.72	100.56	404.07	137.84	157.52
<b>V. Total Expenses</b>	<b>4,214.21</b>	<b>3,389.79</b>	<b>802.70</b>	<b>8,753.19</b>	<b>1,955.41</b>	<b>3,457.22</b>
<b>VI. Profit before tax (III - V)</b>	<b>(133.22)</b>	<b>(79.60)</b>	<b>126.90</b>	<b>(88.21)</b>	<b>228.34</b>	<b>221.18</b>
<b>Tax expense:</b>						
(1) Current tax	15.83	56.88	43.21	89.52	43.21	68.74
(2) Deferred Tax	(30.00)	(18.86)	7.98	(62.58)	6.20	(3.84)
(3) Prior Period Tax	(35.86)	-	-	(35.86)	-	-
<b>VII. Total Tax Expense</b>	<b>(50.03)</b>	<b>38.02</b>	<b>51.19</b>	<b>(8.92)</b>	<b>49.41</b>	<b>64.90</b>
<b>VIII. Profit/(Loss) for the period (VI-VII)</b>	<b>(83.19)</b>	<b>(117.62)</b>	<b>75.71</b>	<b>(79.29)</b>	<b>178.93</b>	<b>156.28</b>
<b>Profit/(loss) Attributable to</b>						
i. Equity Holder of Parent	(43.12)	(66.10)	75.28	12.31	181.25	158.60
ii. Non Controlling Interest	(40.07)	(51.52)	0.43	(91.60)	(2.32)	(2.32)
<b>Other Comprehensive Income/(Loss)</b>						
(i) Items that will not be reclassified to Profit and Loss						
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	(6.22)	(18.07)	(6.93)	(10.03)	0.31	(81.81)
(d) Income tax effect on above	-	-	-	-	-	-
<b>IX. Total Other Comprehensive Income / (Loss)</b>	<b>(6.22)</b>	<b>(18.07)</b>	<b>(6.93)</b>	<b>(10.03)</b>	<b>0.31</b>	<b>(81.81)</b>
<b>X. Total Comprehensive Income/(Loss) for the period (VIII + IX)</b> (Comprising profit and other comprehensive income for the period)	<b>(89.42)</b>	<b>(135.69)</b>	<b>68.78</b>	<b>(89.32)</b>	<b>179.24</b>	<b>74.47</b>
<b>Total Comprehensive Income/(Loss) Attributable to</b>						
i. Equity Holder of Parent	(49.34)	(84.17)	68.35	2.28	181.56	76.79
ii. Non Controlling Interest	(40.07)	(51.52)	0.43	(91.60)	(2.32)	(2.32)
<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
<b>Other Equity</b>						<b>990.77</b>
<b>XI. Earning per equity share</b>						
(a) Basic	(0.02)	(0.02)	0.01	(0.01)	0.03	0.02
(b) Diluted	(0.02)	(0.02)	0.01	(0.01)	0.03	0.02



For and on behalf of the Board of  
Genpharmasec Limited

*Soham*

**Soham Chaturvedi**  
(Whole Time Director & CFO)  
DIN : 09629728

Place: Mumbai  
Date: February 09, 2026

**Notes to consolidated unaudited financial results for the quarter and nine months period ended December 31, 2025**

1. The unaudited consolidated financial results of the Company for the quarter ended December 31, 2025, and nine months period ended December 31, 2025, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended.
2. Segment Reporting has been annexed in Annexure 1.
3. The unaudited consolidated financial results of the Company for the quarter and nine months period ended December 31, 2025, have been reviewed by the Audit Committee on February 09, 2026, and subsequently approved by the Board of Directors at their meeting held on February 09, 2026.
4. During the financial year, the Holding Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business. Accordingly, during the current year, the Holding Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 – Inventories. The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended December 31, 2025, is as follows:  
Decrease in Inventories: Rs. 89.32 Lakhs  
Net Impact on Profit Before Tax: Nil  
Net impact on total comprehensive income: Rs. (19.67) Lakhs
5. During the year ended March 31, 2024, the Holding Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.
6. The results for the quarter ended December 31, 2025, are the balancing figures between in respect of the nine-month period ended results as on December 31, 2025, and the figures in respect of the six-month period ended results as on September 30, 2025. Similarly, the results for the quarter ended December 31, 2024, are the balancing figures in respect of the nine-month period ended results as on December 31, 2024, and the figures for the six-month period ended results as on September 30, 2024.

*Sohani*



7. The Government of India has consolidated 29 existing labour legislations into four Labour Codes, namely the Code on Wages, 2019; the Code on Social Security, 2020; the Industrial Relations Code, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively, the “New Labour Codes”), which have been made effective from November 21, 2025.

Based on management’s assessment, including an actuarial valuation, the implementation of the New Labour Codes has not resulted in any material incremental impact on the Group Company’s gratuity obligations. Accordingly, no adjustment has been made in the financial results for the quarter. The Group is evaluating the impact of the New Labour Codes on other areas, including the contract workforce. Management does not expect any material impact. The Group continues to monitor the issuance of relevant Central and State Rules and clarifications and will recognise the impact, if any, in the financial statements.

8. Previous period figures have been regrouped/reclassified, as considered necessary, to confirm with current period presentation, wherever applicable.

*Sohan*



**GENPHARMASEC LIMITED**  
CIN: L24231MH1992PLC323914  
"ANNEXURE - I"

**Statement of Consolidated unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter and Nine Months ended December 31, 2025**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Nine month ended	Nine month ended	Year Ended
	31st December 2025	30th September	31st December	31st December	31st December	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Segment Revenue</b>						
Pharmaceuticals	3,681.83	3,071.70	833.56	7,920.63	1,926.35	3,255.86
Laboratory Testing	22.18	41.05	14.85	100.47	44.86	116.32
Manufacturing & Processing	278.79	150.96	-	429.75	-	-
<b>Total Revenue</b>	<b>3,982.81</b>	<b>3,263.71</b>	<b>848.41</b>	<b>8,450.85</b>	<b>1,971.21</b>	<b>3,372.18</b>
<b>Segment Results (Profit before tax and interest)</b>						
Pharmaceuticals	67.86	145.93	179.17	392.03	364.91	405.56
Laboratory Testing	(35.97)	(37.57)	(49.97)	(114.93)	(101.71)	(136.09)
Manufacturing & Processing	(123.95)	(165.35)	-	(289.31)	-	-
Unallocable	(0.01)	(0.08)	(0.15)	(0.09)	(4.81)	(4.81)
<b>Total</b>	<b>(92.08)</b>	<b>(57.08)</b>	<b>129.05</b>	<b>(12.30)</b>	<b>258.39</b>	<b>264.67</b>
<b>Less</b>						
(i) Unallocated Finance Cost	(41.14)	(22.52)	(2.15)	(75.92)	(30.05)	(43.48)
(ii) Other unallowable expenditure net of unallowable income	-	-	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-	-	-
<b>Profit Before Tax</b>	<b>(133.22)</b>	<b>(79.60)</b>	<b>126.90</b>	<b>(88.21)</b>	<b>228.34</b>	<b>221.18</b>
<b>Segment Assets</b>						
Pharmaceuticals	6,102.80	6,633.33	3,046.16	6,102.80	3,046.16	2,329.91
Laboratory Testing	806.81	959.72	778.20	806.81	778.20	880.59
Manufacturing & Processing	2,158.59	2,982.77	-	2,158.59	-	-
Un-Allocated	1,827.82	1,823.68	4,312.21	1,827.82	4,312.21	4,778.72
<b>Total</b>	<b>10,896.02</b>	<b>12,399.50</b>	<b>8,136.56</b>	<b>10,896.02</b>	<b>8,136.56</b>	<b>7,989.22</b>
<b>Segment Liabilities</b>						
Pharmaceuticals	3,842.76	4,408.13	1,046.53	3,842.76	1,046.53	1,365.18
Laboratory Testing	156.30	820.97	42.49	156.30	42.49	96.09
Manufacturing & Processing	417.97	606.26	-	417.97	-	-
Un-Allocated	9.56	5.41	356.81	9.56	356.81	-
<b>Total</b>	<b>4,426.59</b>	<b>5,840.76</b>	<b>1,445.83</b>	<b>4,426.59</b>	<b>1,445.83</b>	<b>1,461.27</b>

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).



For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*

**Sohan Chaturvedi**  
(Whole Time Director & CFO)  
DIN : 09629728

Place: Mumbai  
Date: February 09, 2026